tiprankstipranks
Eco Animal Health Group PLC (GB:EAH)
LSE:EAH
Want to see GB:EAH full AI Analyst Report?

Eco Animal Health (EAH) AI Stock Analysis

6 Followers

Top Page

GB:EAH

Eco Animal Health

(LSE:EAH)

Select Model
Select Model
Select Model
Outperform 76 (OpenAI - 5.2)
Rating:76Outperform
Price Target:
106.00 p
▲(35.03% Upside)
Action:ReiteratedDate:12/07/25
Eco Animal Health's overall stock score is driven by strong technical momentum and positive corporate events, indicating confidence in future growth. However, the high valuation and inconsistent financial performance temper the score, suggesting potential risks if growth expectations are not met.
Positive Factors
Strong balance sheet
A conservative leverage profile and healthy equity ratio give the company durable financial flexibility. This reduces refinancing risk, supports continued R&D and regulatory submissions, and allows the business to absorb cyclical livestock market swings while funding commercialization without immediate external funding.
Negative Factors
Inconsistent revenue growth
Erratic top-line trends and a recent revenue decline weaken medium-term visibility for investments and margins. Inconsistent growth complicates forecasting for product rollouts and partner commitments, and may indicate challenges in commercial execution or market penetration that persist over multiple quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet
A conservative leverage profile and healthy equity ratio give the company durable financial flexibility. This reduces refinancing risk, supports continued R&D and regulatory submissions, and allows the business to absorb cyclical livestock market swings while funding commercialization without immediate external funding.
Read all positive factors

Eco Animal Health (EAH) vs. iShares MSCI United Kingdom ETF (EWC)

Eco Animal Health Business Overview & Revenue Model

Company Description
Eco Animal Health (EAH) is a global provider of innovative animal health products, specializing in sustainable solutions for livestock and aquaculture. The company focuses on developing environmentally friendly medications and nutritional products...
How the Company Makes Money
EAH primarily makes money by selling animal health pharmaceutical products for livestock markets. Revenue is generated through (1) product sales via EAH’s own sales and distribution operations in markets where it has direct presence, and (2) sales...

Eco Animal Health Financial Statement Overview

Summary
Eco Animal Health demonstrates a stable financial position with a strong balance sheet and improving cash flow generation. However, inconsistent revenue growth and low net profit margins present challenges to future profitability.
Income Statement
65
Positive
Balance Sheet
75
Positive
Cash Flow
70
Positive
BreakdownTTMMar 2024Mar 2023Mar 2022Mar 2021Sep 2020
Income Statement
Total Revenue85.81M79.60M89.42M85.31M82.19M105.61M
Gross Profit42.10M35.91M37.68M36.75M33.70M51.54M
EBITDA9.60M7.29M6.53M7.41M3.62M18.63M
Net Income3.02M1.69M1.05M1.01M-686.00K7.34M
Balance Sheet
Total Assets113.96M120.60M123.27M121.31M113.60M116.89M
Cash, Cash Equivalents and Short-Term Investments18.64M25.01M22.37M21.66M14.31M19.52M
Total Debt5.06M3.79M4.03M4.48M1.91M1.52M
Total Liabilities21.57M25.84M29.89M25.76M19.25M21.57M
Stockholders Equity84.75M85.50M83.69M83.27M82.06M81.90M
Cash Flow
Free Cash Flow8.66M5.44M4.94M10.03M-3.25M11.04M
Operating Cash Flow8.99M10.45M9.42M16.01M-358.00K12.11M
Investing Cash Flow-5.20M-4.61M-3.42M-5.98M-2.88M-1.06M
Financing Cash Flow-3.33M-1.95M-3.69M-2.40M-3.31M-684.00K

Eco Animal Health Technical Analysis

Technical Analysis Sentiment
Positive
Last Price78.50
Price Trends
50DMA
100.42
Negative
100DMA
102.71
Negative
200DMA
91.36
Positive
Market Momentum
MACD
-0.57
Negative
RSI
53.24
Neutral
STOCH
78.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:EAH, the sentiment is Positive. The current price of 78.5 is below the 20-day moving average (MA) of 96.72, below the 50-day MA of 100.42, and below the 200-day MA of 91.36, indicating a neutral trend. The MACD of -0.57 indicates Negative momentum. The RSI at 53.24 is Neutral, neither overbought nor oversold. The STOCH value of 78.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:EAH.

Eco Animal Health Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
£63.69M-44.803.55%1.44%359.79%
67
Neutral
£229.23M15.482.63%2.18%8.74%-166.50%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:EAH
Eco Animal Health
91.00
21.50
30.94%
GB:ANCR
Animalcare
332.00
99.79
42.97%

Eco Animal Health Corporate Events

Business Operations and StrategyExecutive/Board ChangesProduct-Related Announcements
ECO Animal Health hires business development chief to drive next growth phase
Positive
Apr 14, 2026
ECO Animal Health Group has appointed Dr Andrew Winder as Head of Business Development, effective 11 May 2026, to bolster strategic growth across its global animal health portfolio. Winder, who joins from Norbrook Laboratories where he led major c...
Business Operations and StrategyExecutive/Board Changes
ECO Animal Health Announces Retirement of Non‑Executive Director Frank Armstrong
Positive
Mar 31, 2026
ECO Animal Health has announced that Independent Non‑Executive Director Frank Armstrong will retire from the board following the company’s Annual General Meeting, expected in September, as he prepares to assume the role of Senior Lay M...
Business Operations and StrategyFinancial Disclosures
Eco Animal Health lifts full-year outlook as margins beat forecasts
Positive
Mar 19, 2026
Eco Animal Health said trading for the year to 31 March 2026 remained strong, extending a robust first half, with full-year revenue expected to grow by about 8% year on year to slightly above market expectations. Growth was driven in particular by...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
ECO Animal Health Wins Key USDA Safety Milestone for New Poultry Vaccine
Positive
Mar 11, 2026
ECO Animal Health has received a favourable safety assessment from the U.S. Department of Agriculture for ECOVAXXIN MG, its live poultry vaccine targeting the respiratory pathogen Mycoplasma gallisepticum. This review confirms that the vaccine mee...
Business Operations and StrategyRegulatory Filings and Compliance
Eco Animal Health Leaves 375,505 Shares Available Under Option Schemes
Positive
Mar 5, 2026
Eco Animal Health Group has provided an update on its block listing related to its Executive and Unapproved Share Option Schemes, originally covering 1.5 million ordinary shares admitted in 2017. Over the latest reporting period to 12 February 202...
Business Operations and StrategyProduct-Related Announcements
ECO Animal Health sets EU launch plan for new poultry vaccine ECOVAXXIN MS
Positive
Feb 26, 2026
ECO Animal Health Group has outlined its EU commercial launch strategy for ECOVAXXIN® MS, a poultry vaccine targeting Mycoplasma synoviae in layer and breeder chickens, following European Commission marketing authorisation granted in late 202...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 07, 2025